ArticleThe American journal of case reports2026
Methylene Blue Rescue Therapy for Vasoplegic Shock After Antihypertensive Drug Overdose.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND ß-blocker and calcium channel blocker overdose typically manifests with bradycardia and hypotension. Progression to refractory shock may occur in cases of severe toxicity, requiring vasopressor support. Methylene blue is a nitric oxide synthase inhibitor that can be used in vasoplegic shock refractory to vasopressor therapy. This report describes a case of refractory shock treated with methylene blue as rescue therapy after an overdose of multiple prescribed antihypertensive agents. CASE REPORT A 47-year-old woman was admitted after a suicide attempt involving an overdose of a ß-blocker and a combination of a calcium channel blocker and an angiotensin receptor blocker. She was initially hemodynamically stable; however, she developed sudden-onset bradycardia, hypotension, and progressive shock while in the emergency department. Initial management included atropine, calcium gluconate, glucagon, a high-dose dextrose-insulin infusion, and 3 vasopressors. Despite these interventions, she displayed profound hypotension and shock. Due to persistent refractory vasodilatory shock, a bolus of methylene blue was administered within 48 h of intensive care unit admission, resulting in a substantial and rapid improvement in blood pressure, as well as successful weaning from vasopressors within 72 h after administration. CONCLUSIONS This case indicates that methylene blue can serve as a rescue therapy option for managing refractory vasoplegic shock induced by overdose of antihypertensives, including calcium channel blockers, ß-blockers, and angiotensin receptor blockers. It contributes to the growing body of evidence supporting the use of methylene blue in refractory vasoplegia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.